Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

Blood

Volumn 105, Issue 10, 2005, Pages 4115-4119

  Rondelli, Damiano ^a   Barosi, Giovanni ^b   Bacigalupo, Andrea ^b   Prchal, Josef T ^b   Popat, Uday ^b   Alessandrino, Emilio P ^b   Spivak, Jerry L ^b   Douglas Smith, B ^b   Klingemann, Hans G ^b   Fruchtman, Steven ^b   Hoffman, Ronald ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; FLUDARABINE; HYDROXYUREA; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; THALIDOMIDE; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHIMERA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HLA SYSTEM; HUMAN; INFECTION; LEUKOCYTE TRANSFUSION; LIVING DONOR; MALE; MYELOFIBROSIS; MYELOFIBROSIS WITH MYELOID METAPLASIA; MYELOID METAPLASIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; SURVIVAL; WHOLE BODY RADIATION;

EID: 20844457922     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-11-4299     Document Type: Article

References (30)

1. Smith BD, Moliterno AR. Biology and management of idiopathic myelofibrosis. Curr Opin Oncol. 2001;13:91-94.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
3. Barosi G. Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am. 2003;17:1211-1226.
4. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
5. Dupriez B, Demory JL, Lai JL, Fenaux P, Bauters F. Prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1989;73:136-137.
6. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
7. Tefferi A, Deeg HJ. Deciding on transplantation for myelofibrosis: setting the record straight. Mayo Clin Proc. 2004;79:953-954.
8. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78:533-538.
9. Mesa RA. The therapy of myelofibrosis: targeting pathogenesis. Int J Hematol. 2002;76(suppl 2): 296-304.
10. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase Il trial. J Clin Oncol. 2004;22:424-431.
11. Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: experience in 6 patients and meta-analytical approach. Haematologica. 1998;83:616-621.
12. Li Z, Deeg HJ, Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia. 2001;15:465-467.
13. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831-2838.
14. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35-40.
15. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
16. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807-813.
17. Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med. 2000;343:659; author reply 659-660.
18. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
19. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
20. Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant. 2003;9:453-459.
21. Alessandrino EP, Bernasconi P, Colombo AA, et al. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol. 2001;80:521-524
22. Bacigalupo A, Van Lint MT, Valbonesi M, et al. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood. 1996;88:353-357.
23. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant. 1999;23:1055-1060.
24. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol. 1971;56:24-31.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
26. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-259.
27. Ni H, Barosi G, Rondelli D, Hottman R. Studies of the site and distribution of CD34+ cells in idyopathic myelofibrosis. Am J Clin Path. In press.
28. Byrne JL, Beshti H, Clark D, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneictransplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol. 2000;108:430-433.
29. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26:697-699.
30. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003;9:52-59.